• Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? (bmj.com)
  • Potential risk factors for toxicity were recorded on each patient. (elsevierpure.com)
  • High doses or accidental overdose of Methotrexate can lead to severe toxicity, which can be life-threatening. (prescriptiongiant.com)
  • Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK. (consultantlive.com)
  • Previous studies, in other clinical settings, have suggested that polymorphisms in key folate metabolising enzymes such as 5,10- methylenetetrahydrofolate reductase (MTHFR) influence both toxicity and efficacy of methotrexate . (bvsalud.org)
  • Administration of intravenous iodinated radiocontrast agents can cause life-threatening toxicity in patients receiving methotrexate. (ekja.org)
  • The patient developed severe methotrexate toxicity, leading to fatal multiorgan failure and death following repeated contrast imaging with intravenous iohexol. (ekja.org)
  • Even though low-dose oral methotrexate has minor adverse effects, life-threatening toxicity can be precipitated in the presence of iodinated contrast agents. (ekja.org)
  • We report a case of severe MTX toxicity leading to fatal multiorgan dysfunction in a patient on low-dose oral MTX who received two doses of an iodinated contrast agent. (ekja.org)
  • Beryllium Toxicity: How Should Patients Exposed to Beryllium Be Treated and Managed? (cdc.gov)
  • Dosage and duration of calcium folinate rescue primarily depend on the type and dosage of methotrexate therapy, the occurrence of toxicity symptoms, and the individual excretion capacity for methotrexate. (janusinfo.se)
  • Higher rates of retention, which were seen at the higher doses of parenteral methotrexate, suggest better efficacy compared to the lower doses. (medpagetoday.com)
  • To evaluate the safety and efficacy of abatacept plus methotrexate (MTX) over 5 years in patients with rheumatoid arthritis. (jrheum.org)
  • We describe safety analyses for all patients who received at least 1 dose of abatacept and efficacy analyses for the original ~10 mg/kg abatacept-treated group, over 5 years. (jrheum.org)
  • This Phase IIb study demonstrated the safety and efficacy of abatacept plus methotrexate (MTX) over 1 year of double-blind (DB) treatment in patients with RA and an inadequate response to MTX 3 , 4 , and confirmed ~10 mg/kg to be the most effective dose. (jrheum.org)
  • Subsequent Phase III studies verified the efficacy and safety of abatacept both in patients with an inadequate response to MTX 5 and in patients with an inadequate response to anti-TNF agents 6 . (jrheum.org)
  • We report on the safety and tolerability of all patients who received at least 1 dose of abatacept over 5 years, and the efficacy and health-related quality of life (HRQOL) of patients who had received ~10 mg/kg abatacept over 5 years in this continuing open-label extension of a Phase IIb study. (jrheum.org)
  • The aim of the Efficacy and Safety of Etanercept on Active Rheumatoid Arthritis Despite Methotrexate Therapy in Japan (JESMR) study is to compare the efficacy of continuation versus discontinuation of methotrexate (MTX) when starting etanercept (ETN) in patients with active rheumatoid arthritis (RA). (jrheum.org)
  • Therefore, we conducted the Efficacy and Safety of Etanercept on Active Rheumatoid Arthritis Despite Methotrexate Therapy in Japan (JESMR) study to address the differences in clinical activity, radiographic progression, and functional disability over 2 years. (jrheum.org)
  • SAN DIEGO - A split dose of methotrexate (MTX) given orally once per week showed significantly higher efficacy in patients with rheumatoid arthritis (RA) at 16 weeks compared with a single MTX dose weekly, according to new research. (medscape.com)
  • MTX delivered subcutaneously is one way to improve efficacy, but patients can be needle-averse, and in some countries - like India - pre-filled syringes are not available, he said. (medscape.com)
  • OBJECTIVES: To evaluate the efficacy and safety of different doses and regimens of filgotinib, an oral Janus kinase 1 inhibitor, as add-on treatment to methotrexate (MTX) in patients with active rheumatoid arthritis (RA) and inadequate response to MTX. (ox.ac.uk)
  • Results of a systematic review exploring the comparative effectiveness of treatments of early rheumatoid arthritis show that treatment efficacy can be improved with combination therapy with anti-TNF or other biologic medications, compared with methotrexate monotherapy. (wikipedia.org)
  • Our objective was to investigate the impact of two common functional MTHFR polymorphisms, 677C>T and 1298A>C, on the efficacy of methotrexate in women treated for GTN following a molar pregnancy . (bvsalud.org)
  • This study aimed to compare the efficacy and safety of high-dose methotrexate (HD-MTX) versus teniposide (TEN) in patients with newly diagnosed immunocompetent primary central nervous system lymphomas (PCNSLs). (biomedcentral.com)
  • In a comparative study, researchers analyzed the efficacy and safety of flumustine, teniposide, and dexamethasone in patients with central nervous system lymphoma (CNSL). (biomedcentral.com)
  • The first study is "Efficacy and Safety of Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Patients with Non-Radiographic Axial Spondyloarthritis. (medscape.com)
  • The primary efficacy endpoint was the proportion of patients who did not experience a flare of disease activity during the second period. (medscape.com)
  • The investigators looked at whether a temporary discontinuation of methotrexate for 2 weeks after vaccination improved the efficacy of seasonal influenza vaccination in patients with RA. (medscape.com)
  • The subgroup analyses comparing methotrexate exposure with either an immunomodulator alone or immunomodulator and methotrexate combination therapy, as well as patients with rheumatoid arthritis receiving methotrexate, resulted in similar risk estimates. (hcplive.com)
  • A new study reports that discontinuation rates differ between the oral and parenteral formulations, and between the different dosages of parenteral methotrexate. (medpagetoday.com)
  • The time between the first and last prescription of methotrexate was used to calculate the rates of discontinuation. (medpagetoday.com)
  • Discontinuation of methotrexate occurred in 48% of the patients overall. (medpagetoday.com)
  • The main outcome of the investigation was the measure of discontinuation of methotrexate due to abnormal monitoring of blood test results. (consultantlive.com)
  • The cohort was followed up from 6 months after the first prescription of methotrexate in primary care until the earliest of several endpoints, including discontinuation of methotrexate, leaving the practice, death, 5 years, or December 2019. (consultantlive.com)
  • For the purpose of analysis, patients were followed for 1-year from the first date at which remission was recorded until any acute coronary syndrome event or a censoring event, which included first incidence of mortality from any cause other than acute coronary syndrome, emigration, treatment discontinuation of 90 days or longer, new DMARD treatment start, the first non-remission date, or the end of the study. (hcplive.com)
  • The second study looked at temporary methotrexate discontinuation for 2 weeks around the time of seasonal influenza vaccination in patients with rheumatoid arthritis (RA). (medscape.com)
  • Methotrexate (MTX), formerly known as amethopterin, is a chemotherapy agent and immune-system suppressant. (wikipedia.org)
  • Methotrexate was originally developed and continues to be used for chemotherapy, either alone or in combination with other agents. (wikipedia.org)
  • Although originally designed as a chemotherapy drug, in lower doses methotrexate is a generally safe and well-tolerated drug in the treatment of certain autoimmune diseases. (wikipedia.org)
  • methotrexate 35 mg/m 2 i.v. every 3 weeks) is a new combination chemotherapy regimen for advanced breast cancer. (karger.com)
  • Multidrug chemotherapy regimens including high-dose IV methotrexate (1 g/m2 to 8 g/m2) may result in long-lasting responses. (msdmanuals.com)
  • NIOSH staff did not see chemotherapy administration to patients during the visit. (cdc.gov)
  • In breast cancer patients, it is unclear whether measuring p53, mdm-2, or p21 expression provides information on how patients will respond to chemotherapy. (lu.se)
  • p53, mdm-2, p21, and mib-1 expression were not significantly associated with response to chemotherapy, time to progression, or overall survival in the whole patient population or in the docetaxel group. (lu.se)
  • Over the past 40 years, chemotherapy resulted in a progressive improvement in survival rates of patients with malignant neoplasms 1 . (bvsalud.org)
  • Methotrexate (MTX) monotherapy is a common first treatment for rheumatoid arthritis (RA), but many patients do not respond adequately. (elsevierpure.com)
  • Cem Gabay, MD, professor of medicine at the University of Geneva, presented results of a study on the use of sarilumab on circulating biomarkers of bone and joint destruction in patients with rheumatoid arthritis who had shown an inadequate response to methotrexate. (ajmc.com)
  • Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients. (elsevierpure.com)
  • C polymorphisms of MTHFR do not predict response to methotrexate in patients with gestational trophoblastic neoplasia. (bvsalud.org)
  • Response to methotrexate was evaluated with reference to serial human chorionic gonadotrophin (hCG) levels in patient serum . (bvsalud.org)
  • No significant association was found between the genotype of the patient , or presence of the variant allele , and clinical response to methotrexate therapy for either the 677C>T or the 1298A>C SNP. (bvsalud.org)
  • No significant association was found between the genotypes of the molar tissue and response to methotrexate . (bvsalud.org)
  • Future studies examining the effect of methotrexate continuation after the diagnosis of melanoma are required to inform practice. (hcplive.com)
  • Objective: This in vivo experimental study evaluated the effect of methotrexate on the oral mucosa of mice. (bvsalud.org)
  • We therefore investigated whether infliximab, a chimeric human-mouse anti-TNFalpha monoclonal antibody would provide additional clinical benefit to patients who had active rheumatoid arthritis despite receiving methotrexate. (nih.gov)
  • In an international double-blind placebo-controlled phase III clinical trial, 428 patients who had active rheumatoid arthritis, who had received continuous methotrexate for at least 3 months and at a stable dose for at least 4 weeks, were randomised to placebo (n=88) or one of four regimens of infliximab at weeks 0, 2, and 6. (nih.gov)
  • During 30 weeks, treatment with infliximab plus methotrexate was more efficacious than methotrexate alone in patients with active rheumatoid arthritis not previously responding to methotrexate. (nih.gov)
  • Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). (ox.ac.uk)
  • 3 If the time between prescriptions was more than the planned time, and the calculated dose was less than 80% of the expected dose, the patients were considered non-adherent. (medpagetoday.com)
  • The authors, therefore, suggest that the middle dose of parenteral methotrexate should be used preferentially. (medpagetoday.com)
  • They referenced a study that cited the predictable bioavailability of parenteral methotrexate, in addition to the adverse effects of the oral formulation, as reasons to use that preparation and middle dose. (medpagetoday.com)
  • MTX-CD: Methotrexate cumulative dose. (wjgnet.com)
  • Patients completing the 1-year, double-blind period entered the longterm extension, where all patients received a fixed dose of abatacept ~10 mg/kg. (jrheum.org)
  • However, fewer patients in the split-dose group needed additional disease-modifying antirheumatic drugs (DMARDs) to control disease activity. (medscape.com)
  • Patients had active disease, defined as at least four tender joints and at least two swollen joints, and were not taking any DMARDs except for hydroxychloroquine and/or low-dose prednisolone . (medscape.com)
  • A total of 253 patients were randomly assigned to a single 25-mg dose or a split-dose of MTX once weekly (10 mg in the morning and 15 mg in the evening on the same day). (medscape.com)
  • 001), and a higher percentage of patients in the split-dose group had a EULAR good response. (medscape.com)
  • About three quarters (76.6%) of patients in the split-dose group experienced an improvement of at least 20% in ACR response criteria (ACR20), compared with 52% in the single-dose group. (medscape.com)
  • The split-dose group also had higher proportion of patients achieving ACR50 and ACR70. (medscape.com)
  • Two positive results were the earlier ACR responses in the split-dose group as well as fewer patients in that same group needing to add another DMARD to therapy. (medscape.com)
  • For patients who are not tolerating the oral version, "recommend split-dose or subcutaneous or increasing folic acid over switching to a new DMARD," she said. (medscape.com)
  • In these patients, continuation of all DMARDs at their current dose is conditionally recommended over any dose reduction. (medscape.com)
  • METHODS: In this 24-week phase IIb study, patients with moderate-to-severe active RA receiving a stable dose of MTX were randomised (1:1:1:1:1:1:1) to receive placebo or 50, 100 or 200 mg filgotinib, administered once daily or twice daily. (ox.ac.uk)
  • Comprehensively defining the risk of melanoma associated with low-dose methotrexate is important for clinicians across several medical disciplines. (hcplive.com)
  • A systematic review and meta-analysis indicated that low-dose methotrexate, a commonly used treatment for a variety of inflammatory disorders, exposure was associated with a small increased risk of developing melanoma. (hcplive.com)
  • Despite decades of clinical use, some studies suggest that low-dose methotrexate may be associated with an increased risk of skin cancer. (hcplive.com)
  • Case-control studies, cohort studies, and randomized clinical trials (RCTs) were included from MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov if they analyzed the odds or risk of cutaneous melanoma in individuals who were exposed to low-dose methotrexate and compared with individuals who were unexposed. (hcplive.com)
  • Association Between Low-Dose Methotrexate Exposure and Melanoma A Systematic Review and Meta-analysis. (hcplive.com)
  • Krieckaert, CL , Nurmohamed, MT & Wolbink, GJ 2012, ' Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner ', Annals of the rheumatic diseases , vol. 71, no. 11, pp. 1914-1915. (amsterdamumc.org)
  • Ultimately these findings demonstrated good performance in predicting outcomes in clinically relevant subgroups defined by age group, type of IMID, and methotrexate dose. (consultantlive.com)
  • In older HIV-positive people with or at risk of cardiovascular disease, 24 weeks of low-dose methotrexate (LDMTX) reduced CD8-cell numbers and activation but did not quell other markers of inflammation or improve endothelial function [1]. (natap.org)
  • The patient had been on low-dose oral methotrexate for the previous 5 years, which was discontinued two days before surgery. (ekja.org)
  • The patient received the first intravenous contrast agent injection (iohexol) during diagnostic cerebral angiography one day prior to surgery (50 ml) and the second contrast dose on the first postoperative day (60 ml). (ekja.org)
  • The patient was known to have rheumatoid arthritis and to be taking 15 mg of oral MTX per week for the previous five years, the last dose of which was taken two days prior to admission. (ekja.org)
  • This study provided Class III evidence that the teniposide-based regimen was non-inferior to high-dose methotrexate − based regimen with similar overall responses and long-time survival in immunocompetent patients with PCNSL. (biomedcentral.com)
  • Since the calcium folinate rescue dosage regimen depends heavily on the posology and method of the intermediate- or high-dose methotrexate administration, the methotrexate protocol will dictate the dosage regimen of calcium folinate rescue. (janusinfo.se)
  • refer to the applied intermediate or high dose methotrexate protocol for posology and method of administration of calcium folinate. (janusinfo.se)
  • For example, etanercept (ETN) has been shown to be effective for RA both as a monotherapy and as combination therapy with methotrexate (MTX), and the latter has proved its superiority to the former in MTX-naive patients. (jrheum.org)
  • MTX is a highly utilized, inexpensive drug for RA, but only about 30% of patients can achieve low disease activity or remission on MTX monotherapy, said Varun Dhir, MD, MBBS , of the Postgraduate Institute of Medical Education and Research in Chandigarh, India. (medscape.com)
  • Interpretation: The clinically meaningful prolongation of overall survival and favourable safety profile of pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma support the further evaluation of pembrolizumab as a monotherapy and as part of combination therapy in earlier stages of disease. (unige.ch)
  • One hundred seventy-nine patients with acute nonlymphoblastic leukemia in first remission (n = 75), chronic myelocytic leukemia in chronic or accelerated phase (n = 48) or leukemia in advanced stage (n = 56) were given HLA-identical marrow grafts and randomized to receive methotrexate or cyclosporine for prevention of graft-v-host disease (GVHD). (duke.edu)
  • Tried several drugs for 2 years which didn't work (except Prednisone which my doctor said I couldn't stay on long term) and finally got total remission with Methotrexate. (ihaveuc.com)
  • An analysis of patient data from Sweden and Norway detail the impact of achieving remission with methotrexate or TNF inhibitors on risk of acute coronary syndrome in patients with rheumatoid arthritis. (hcplive.com)
  • An analysis of patient data from a pair of European nations is offering clinicians with insight into the risk of acute coronary syndrome in patients with rheumatoid arthritis based on whether they have attained remission with a methotrexate or a tumor necrosis factor (TNF) inhibitor. (hcplive.com)
  • Results of the study, which were presented at the European Congress of Rheumatology (EULAR) 2023 annual meeting , indicate the risk of acute coronary syndrome was similar for those who achieved remission using methotrexate relative to their counterparts achieving remission with a TNF inhibitor, with overall incidence rates of acute coronary syndrome in patients in remission comparable to the incidence rate in the general population. (hcplive.com)
  • Patients with [rheumatoid arthritis] who reach remission on MTX have a similar ACS risk as those reaching remission on TNF inhibitors," said Bénédicte Delcoigne, PhD, MSc, a statistician from the Karolinska Institutet in Stockholm, Sweden. (hcplive.com)
  • 2 "The incidence rates of [acute coronary syndrome] in patients in remission were comparable to the incidence rate in the general population. (hcplive.com)
  • 3 Citing an interest in exploring differences in risk for acute coronary syndrome based on achievement of remission with either methotrexate or a TNF inhibitor in patients with rheumatoid arthritis, Delcoigne and a team of colleagues from the Karolinska Institute designed the current study as an analysis of data from clinical rheumatology registers in Norway and Sweden. (hcplive.com)
  • For inclusion in the analysis, patients needed to have started therapy with methotrexate or a TNF inhibitor between 2012-2021 while not being in remission. (hcplive.com)
  • Further inclusion criteria required patients to have achieved remission with 90-548 days of beginning treatment and have no history of acute coronary syndrome for at least 5 years preceding study entry. (hcplive.com)
  • Initial analysis indicated DAS28 remission in the allowed time window was achieved in 40% using methotrexate and 4147 using TNF inhibitors. (hcplive.com)
  • During the 1-year follow-up, investigators identified 15 acute coronary syndrome events among those who achieved remission with methotrexate and 12 acute coronary syndrome events among toe who achieved remission with a TNF inhibitor. (hcplive.com)
  • [ 1 ] It has not been known whether TNF blockers can be stopped in patients with nonradiographic axial spondyloarthritis who are in remission. (medscape.com)
  • Of 673 patients who enrolled in the open-label phase, only 305 achieved remission and were randomized to double-blind therapy. (medscape.com)
  • This study concluded that patients with nonradiographic axial spondyloarthritis who achieved remission with open-label adalimumab treatment did better when they continued treatment with adalimumab rather than when adalimumab treatment was withdrawn, supporting the practice of continuing TNF-blocker therapy after sustained remission in nonradiographic axial spondyloarthritis. (medscape.com)
  • Incidence rates of adverse events (AE) and serious AE were 489.7 and 20.0/100 patient-years in Year 1 versus 374.9 and 18.9/100 patient-years in the cumulative period, respectively. (jrheum.org)
  • Folic acid is commonly co-prescribed with methotrexate to minimise the risk of adverse effects. (wikipedia.org)
  • In some patients, it may be advantageous to initiate therapy with a dosage of 1-2 g daily to lessen adverse GI effects. (drugs.com)
  • 2 g daily must be weighed against the risks of increased adverse effects and the necessity for more careful patient monitoring. (drugs.com)
  • Fewer patients treated with pembrolizumab than with standard of care had grade 3 or worse treatment-related adverse events (33 [13%] of 246 vs 85 [36%] of 234). (unige.ch)
  • Among patients who were treated with adalimumab at any time, 77% reported adverse events and 4% reported a serious adverse event. (medscape.com)
  • During period 2, the incidence of adverse events was similar for patients treated with adalimumab and those in whom adalimumab had been discontinued. (medscape.com)
  • Surprisingly, serious adverse events were higher for patients treated with placebo and discontinuing adalimumab-7%-compared with 1%, and the most common adverse events in both groups were nasopharyngitis, upper respiratory tract infection , and the report of worsening of axial spondyloarthritis disease activity. (medscape.com)
  • Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. (nih.gov)
  • There is some evidence that concomitant therapy with sulfasalazine and corticosteroids may not be more effective than either drug alone, but some subgroups of patients may have a better response to combined therapy (e.g., those with disease localized in the colon). (drugs.com)
  • For patients with alopecia areata (AA), corticosteroids are the most commonly used treatment, and by one year, 71.8 percent are receiving no treatment, according to a study published online Sept. 20 in JAMA Dermatology. (medicalxpress.com)
  • Thus, corticosteroids should not be given to patients with suspected CNS lymphoma until after definitive diagnosis, unless absolutely necessary because of acute clinical deterioration. (msdmanuals.com)
  • All patients who completed the 1-year, DB period of this study (clinical trial registration number: NCT00254293) 3 , 4 were eligible to enter the open-label LTE period. (jrheum.org)
  • Because MTX is the first-line drug for most patients with RA, and ETN is much more expensive than MTX, ETN tends to be started for MTX-refractory, but not MTX-naive, patients in actual clinical practice 3 , 4 . (jrheum.org)
  • 80) and/or are taking may be associated with subjective and objective antihypertensive medications.2 Medications measures of adherence.7 are required in most patients with hypertension to control their blood pressure and to prevent heart disease.3 However, poor adherence to antihypertensive medications have a negative impact on clinical outcomes. (cdc.gov)
  • A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol. (ox.ac.uk)
  • Our data have provided evidence for a comparable prediction of clinical outcome in CMF-treated breast cancer patients using conventional clinical variables and gene expression based markers. (lu.se)
  • Adjuvant polychemotherapy (e.g. with 58% to 68%) for patients under the age of 50.1 Besides an cyclophosphamide, methotrexate and 5-fluorouracil (CMF)) or improvement in clinical outcome, these figures indicate that anthracycline-containing regimes, produce substantial reduc- a large proportion of the patients will never recur after the tion in recurrence and mortality. (lu.se)
  • Data on the patient's history of psoriasis and psoriatic arthritis, clinical findings, nail involvement, and patient- and practitioner-reported outcomes were collected from standardized questionnaires. (medscape.com)
  • Prospective assessment of the clinical benefit of a tailored cancer gene set built on a next-generation sequencing platform in patients with recurrent or metastatic head and neck cancer. (cdc.gov)
  • Clinical utility of miRNA-1, miRNA-29g and miRNA-133s plasma levels in prostate cancer patients with high-intensity training after androgen-deprivation therapy. (cdc.gov)
  • Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients. (cdc.gov)
  • Even though methotrexate has been proven effective in treating psoriatic arthritis (PsA)-and thus has been included in treatment guidelines for the condition-adherence to this therapy has been poor in both its oral and injectable (subcutaneous and intramuscular) forms. (medpagetoday.com)
  • The risk of lymphoma is increased in patients with rheumatoid arthritis (RA), and spontaneous reporting suggests that methotrexate (MTX) and anti-tumor necrosis factor (anti-TNF) therapy might be associated independently with an increased risk of lymphoma. (nih.gov)
  • The increased lymphoma rates observed with anti-TNF therapy may reflect channeling bias, whereby patients with the highest risk of lymphoma preferentially receive anti-TNF therapy. (nih.gov)
  • Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? (biomedcentral.com)
  • This finding provides information to better inform patients when initiating methotrexate therapy. (hcplive.com)
  • Patients who have previously received corticosteroid therapy or have undergone surgical resection may fail to respond to sulfasalazine therapy. (drugs.com)
  • The patients received HD-MTX or TEN as first-line induction therapy. (biomedcentral.com)
  • Exploiting the genetic basis of these tumours enables us to develop a more tailored approach to therapy for patients with BRCA mutated cancers. (ox.ac.uk)
  • For patients with impairing CBD, corticosteroid therapy continues to be the primary treatment modality (Glazer and Newman 2003). (cdc.gov)
  • Patients should be monitored for therapy-induced side effects on an ongoing basis. (cdc.gov)
  • Radiotherapy was delivered to ipsilateral axil- cancer patients in the future, it is essential to increase our lary and supraclavicular lymph nodes and the remaining knowledge in mechanisms responsible for drug resistance, breast parenchyma after breast conservation surgery or tho- and to define reliable indicators for response to therapy. (lu.se)
  • Seventy percent of the patients who continued adalimumab therapy, compared with 47% who discontinued adalimumab, flared at week 68. (medscape.com)
  • Investigators in Italy recently found that about 50% of patients who are prescribed methotrexate to treat their psoriatic arthritis (PsA) eventually discontinue the medication. (medpagetoday.com)
  • Are you being prescribed methotrexate to treat your disease? (ihaveuc.com)
  • The model, developed through a retrospective cohort study, has demonstrated impressive accuracy in predicting the risk of discontinuing methotrexate due to abnormal monitoring of blood test results. (consultantlive.com)
  • The team's goal is that the model can be used to stratify the risk of discontinuing methotrexate due to abnormal blood test monitoring during long-term treatment. (consultantlive.com)
  • SEE NAMCS PATIENT DATASET NAMES FOR DSN ABSTRACT General Information This material provides documentation for users of the Micro-Data tapes of the National Ambulatory Medical Care Survey (NAMCS) conducted by the National Center for Health Statistics. (cdc.gov)
  • DSN: CC37.NAMCS90.PATIENTS ABSTRACT This material provides documentation for users of the Micro-Data tapes of the National Ambulatory Medical Care Survey (NAMCS) conducted by the National Center for Health Statistics. (cdc.gov)
  • METHODS: This multi-centre phase II single arm trial was designed to investigate the activity and safety of 6-mercaptopurine (6MP) 55 mg/m² per day, and methotrexate 15 mg/m² per week in patients with advanced breast or ovarian cancer, ECOG PS 0-2, progressing after ≥ one prior regimen and known to bear a BRCA1/2 germ line mutation. (ox.ac.uk)
  • Patients and methods proportion of the patients will recur despite treatment with adjuvant polychemotherapy. (lu.se)
  • p53, mdm-2, p21, and mib-1 expression were assessed by immunohistochemical methods in primary tumors derived from 134 patients who took part in a randomized multicenter trial comparing docetaxel to sequential methotrexate and 5-fluorouracil (MF) in advanced breast cancer. (lu.se)
  • Patients with evidence of early lung damage are treated with 40 mg of prednisone on a daily or alternate day regimen for 6 months. (cdc.gov)
  • Though preferred in the treatment of PsA, methotrexate is often associated with poor adherence rates. (medpagetoday.com)
  • The objective of this study was to determine the rate of and standardized incidence ratio (SIR) for lymphoma in patients with RA and in RA patient subsets by treatment group. (nih.gov)
  • Not all patients with rheumatoid arthritis can tolerate or respond to methotrexate, a standard treatment for this disease. (nih.gov)
  • New proposed guidelines for managing rheumatoid arthritis (RA) recommend that methotrexate (MTX) be used aggressively before other treatment options. (medscape.com)
  • Patients receiving methotrexate treatment may be more likely to be diagnosed with melanoma as they are more engaged with the healthcare system, thus creating the possibility of detection bias in the observational studies. (hcplive.com)
  • Methotrexate is one of the first-line therapies for the treatment of rheumatoid arthritis. (wikipedia.org)
  • Likewise, a 2016 study found the use of methotrexate, in combination with anti-TNF agents, has been shown to be effective for the treatment of ulcerative colitis. (wikipedia.org)
  • In the first trial, which involved 227 patients, 53% of patients receiving MMM and 49% receiving VAC responded to treatment. (karger.com)
  • In the second trial, which involved 120 patients, 51% of patients receiving MMM and 60% receiving CMF responded to treatment. (karger.com)
  • Both men and women taking Methotrexate should use contraception during treatment and for a period afterward. (prescriptiongiant.com)
  • Methotrexate is a common first-line treatment for rheumatoid arthritis (RA), an autoimmune disease that causes joint inflammation and pain. (prescriptiongiant.com)
  • Background: There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. (unige.ch)
  • Treatment-related death occurred in four patients treated with pembrolizumab (unspecified cause, large intestine perforation, malignant neoplasm progression, and Stevens-Johnson syndrome) and two patients treated with standard of care (malignant neoplasm progression and pneumonia). (unige.ch)
  • A newly developed prognostic model could revolutionize the monitoring of long-term methotrexate treatment, a commonly prescribed medication for immune-mediated inflammatory diseases. (consultantlive.com)
  • Regular monitoring of a patient's blood is crucial during long-term methotrexate treatment in order to detect potential abnormalities and ensure patient safety. (consultantlive.com)
  • To address this issue, a retrospective cohort study was conducted to develop and validate a prognostic model that can inform risk-stratified decisions on the frequency of monitoring blood tests during long-term methotrexate treatment. (consultantlive.com)
  • Overall, investigators identified 14,488 treatment courses with methotrexate and 13,056 with TNF inhibitors during the period of interest. (hcplive.com)
  • Among them, a significant portion of elderly patients aged 70 or older cannot tolerate HD-MTX, and other equivalent drugs or treatment options for those patients are currently lacking. (biomedcentral.com)
  • if not, then accrual would proceed to a second stage, in which if more than 9/65 evaluable patients are found to respond at 8 weeks, the treatment will be regarded as potentially effective and a phase III trial considered subject to satisfactory safety and tolerability. (ox.ac.uk)
  • Most patients are diagnosed at an advanced stage, which leaves them with few treatment options. (medicalxpress.com)
  • Patients who are sensitized to beryllium but do not yet have the disease do not need any treatment. (cdc.gov)
  • Patients who have early beryllium disease but do not yet have symptoms may not require treatment. (cdc.gov)
  • Possible mechanisms for gram for breast cancer in southern Sweden issued 1991, pre- recurrence after treatment are low initial drug sensitivity or menopausal lymph node positive (N+) breast cancer patients an acquired drug resistance. (lu.se)
  • Patients who achieved an Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease level, when treated during the open-label phase with adalimumab 40 mg subcutaneously every other week at weeks 16, 20, 24, and 28, were randomized to participate in a 40-week double-blind placebo or adalimumab treatment in period 2. (medscape.com)
  • At the beginning of last century, the only treatment available for patients with solid tumors was surgery, associated with high morbidity and mortality. (bvsalud.org)
  • In addition to calcium folinate administration, measures to ensure the prompt excretion of methotrexate (maintenance of high urine output and alkalinisation of urine) are integral parts of the calcium folinate rescue treatment. (janusinfo.se)
  • Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization will be used to divide the study sample into two groups .Unit of randomization will be individual with the help of giving random sealed envelope to the patients. (who.int)
  • Patients or the neutral assessor will know about the treatment modality used. (who.int)
  • Methotrexate is a medication commonly used to treat various medical conditions, including rheumatoid arthritis, psoriasis, and certain types of cancer. (prescriptiongiant.com)
  • Methotrexate is used to manage severe psoriasis, a chronic skin condition characterized by scaly and inflamed patches. (prescriptiongiant.com)
  • Methotrexate is commonly prescribed for immune-mediated inflammatory diseases (IMIDs) such as rheumatoid arthritis (RA) , psoriasis (PsO) , and i nflammatory bowel disease (IBD) . (consultantlive.com)
  • it only occurs in less than 5% of patients with no other cutaneous findings of psoriasis. (medscape.com)
  • An estimated 10-55% of all patients with psoriasis have psoriatic nail disease, and approximately 7 million people in the United States have psoriasis. (medscape.com)
  • US physicians see 1.5 million patients with psoriasis per year. (medscape.com)
  • This patient has extensive psoriasis, nail involvement, and joint pain. (medscape.com)
  • For patient education information, see the Psoriasis Center and Arthritis Center, as well as Psoriasis, Types of Psoriasis, Understanding Psoriasis Medications, and Psoriatic Arthritis. (medscape.com)
  • Psoriatic nail disease occurs in 10-55% of all patients with psoriasis, and approximately 7 million people in the United States have psoriasis (psoriasis affects 2-3% of the US population). (medscape.com)
  • Less than 5% of psoriatic nail disease cases occur in patients without other cutaneous findings of psoriasis. (medscape.com)
  • About 10-20% of people with psoriasis also have psoriatic arthritis, and nail changes are seen in 53-86% of patients with psoriatic arthritis. (medscape.com)
  • [ 3 ] 36% of patients reported the presence of psoriasis in at least 1 relative. (medscape.com)
  • A retrospective study from 2014 reports that nail involvement in psoriasis is a significant predictor of the patient also having psoriatic arthritis. (medscape.com)
  • [ 4 ] The study looked at retrospective data from three German cross-sectional independent national studies on patients with psoriasis and psoriatic arthritis. (medscape.com)
  • Sometimes, if a drug is not compatible with methotrexate, it would be necessary to discontinue the other medication or switch it out for another one. (rawarrior.com)
  • If your answer is "yes", you can read the different patient reviews of methotrexate below, and if you are currently or have previously taken the medication you can add your review. (ihaveuc.com)
  • Here is an informational page from the National Institute of Health on the medication - methotrexate info page . (ihaveuc.com)
  • Methotrexate is available as a generic medication. (wikipedia.org)
  • Methotrexate (MTX) remains the most commonly used disease modifying antirheumatic drug in rheumatoid arthritis (RA) because of its cost and experience in its use, despite the availability of new treatments such as leflunomide and the biological agents. (bmj.com)
  • There's a strong emphasis on maximizing methotrexate using various means before switching to a biologic or JAK [Janus kinase] inhibitor," she said in a press conference at ACR Convergence 2020. (medscape.com)
  • Investigators noted this corresponds with crude incidence rates of 3.4 (95% Confidence interval [CI], 2.0-5.6) and 3.8 (95% CI, 2.2-6.7) events per 1000 person-years for the methotrexate and TNF inhibitor groups, respectively. (hcplive.com)
  • Use of low doses of methotrexate together with NSAIDs such as aspirin or analgesics such as paracetamol is relatively safe in people being treated for rheumatoid arthritis, with appropriate monitoring. (wikipedia.org)
  • Methotrexate can be given by mouth or by injection (intramuscular, intravenous, subcutaneous, or intrathecal). (wikipedia.org)
  • The patient was monitored in the neurocritical care unit in the immediate postoperative period and was treated with intravenous levetiracetam, mannitol, and paracetamol. (ekja.org)
  • Patient will be given methotrexate to apply as few drops on the affected area once daily for 3 days after procedure. (who.int)
  • Other common side effects of methotrexate include increased risk with infection and greater chance of sunburn, either of which may also be more severe with methotrexate. (rawarrior.com)
  • In severe cases, patients may have functional and psychosocial impairments. (medscape.com)
  • Methotrexate is an abortifacient and is used to treat ectopic pregnancies, provided the fallopian tube has not ruptured. (wikipedia.org)
  • In some cases, Methotrexate may be used to treat ectopic pregnancies, where a fertilized egg implants outside the uterus. (prescriptiongiant.com)
  • Methotrexate is used in higher doses to treat certain types of cancer, such as leukemia, lymphoma, and some types of solid tumors. (prescriptiongiant.com)
  • Part of the problem is that "oral methotrexate absorption from the gut reduces as the doses go up," Dhir noted, because the transport mechanism gets saturated. (medscape.com)
  • At week 12, significantly more patients receiving filgotinib 100 mg once daily or 200 mg daily (both regimens) achieved an ACR20 response versus placebo. (ox.ac.uk)
  • As of May 15, 2017, 181 (73%) of 247 patients in the pembrolizumab group and 207 (83%) of 248 patients in the standard-of-care group had died. (unige.ch)
  • Jo Methotrexate cause much hair loss, but it is hard to know if it caused any other side effects due to multiple medications. (ihaveuc.com)
  • Fraenkel, an adjunct professor at Yale School of Medicine in New Haven, Connecticut, said the exception for maximizing MTX would be for patients with low disease activity for whom treatments with other medications, such as hydroxychloroquine (HCQ) and sulfasalazine, are feasible, she said. (medscape.com)
  • Addressing patient attitudes may aid antihypertensive medications with either in developing interventions to target explicit positive or negative connotations. (cdc.gov)
  • Methotrexate can interact with various drugs, so it's crucial to inform your healthcare provider about all the medications you are taking to avoid potential complications. (prescriptiongiant.com)
  • While there are lots of antibiotics and many NSAIDs and herbal anti-inflammatories, there is only one methotrexate. (rawarrior.com)
  • Castiella A, Lopez-Dominguez L, Sanchez-Iturri MJ, Urreta I, De Diego A, Belzunegui J, Zapata E. Liver steatosis in patients with rheumatoid arthritis treated with methotrexate is associated with body mass index. (wjgnet.com)
  • Methotrexate can lead to liver cirrhosis or liver fibrosis. (rawarrior.com)
  • For this reason, rheumatologists usually require patients to submit to regular tests of liver function. (rawarrior.com)
  • Nonalcoholic fatty liver disease could be the underlying risk factor for transaminase elevation in patients with hyperlipidemia and obesity. (elsevierpure.com)
  • Methotrexate can affect the liver, potentially leading to liver damage or elevated liver enzymes. (prescriptiongiant.com)
  • For methotrexate, nausea and vomiting are very common, especially with the oral preparation. (medpagetoday.com)
  • Incidence of neuropathy, alopecia, and nausea and vomiting was significantly higher in patients receiving VAC. (karger.com)
  • Methotrexate can cause nausea, vomiting, and diarrhea. (prescriptiongiant.com)
  • Patients were randomized to abatacept 10 or 2 mg/kg or placebo, plus MTX. (jrheum.org)
  • Serious infections occurred in one and five patients in the placebo and filgotinib groups, respectively. (ox.ac.uk)
  • A significantly greater proportion of patients treated with adalimumab during the second phase, compared with those who were treated with placebo, in whom adalimumab had been discontinued, had no flares at week 68. (medscape.com)
  • An analysis of time-to-flare showed a significantly lower risk of flaring for patients continuing adalimumab compared with those treated with placebo and discontinuing adalimumab. (medscape.com)
  • As multidisciplinary care has become more of a focal point in the management of patients, interest has grown in managing the increased cardiovascular risk associated with rheumatic disease, including a recent systematic review and meta-analysis, which found use of TNF inhibitors was associated with a favorable effect on surrogate markers for cardiovascular disease risk. (hcplive.com)
  • Prognostic significance of microRNA-135 in patients with digestive system cancers: a systematic review and meta-analysis. (cdc.gov)
  • The probabilities of survival for cyclosporine-v methotrexate-treated patients were comparable for all three study groups: 52% v 48% in patients with acute nonlymphoblastic leukemia (P = .42), 55% v 60% for those with chronic myelocytic leukemia (P = .61), 12% and 12% for those with advanced leukemia (P = .93), and 39% v 38% overall (P = .72). (duke.edu)
  • We conclude that cyclosporine and methotrexate are comparable regarding the likelihood of acute/chronic GVHD, interstitial pneumonia, leukemic relapse, and long-term survival. (duke.edu)
  • The objective response rate, progression-free survival, and overall survival were analyzed for each patient cohort. (biomedcentral.com)
  • Influence of family history on risk of second primary cancers and survival in squamous cell skin cancer patients. (cdc.gov)
  • One WUPyV-infected patient who exhibited acute nature of the study, French law did not require ethical ap- respiratory failure had concomitant pneumonia caused by proval or informed consent. (cdc.gov)
  • Expectant management of ectopic pregnancy: which patients are appropriate? (isuog.org)
  • Methotrexate is sometimes used to treat children with juvenile idiopathic arthritis (JIA), a form of arthritis that affects children. (prescriptiongiant.com)
  • At week 68, significantly greater proportions of patients continuing adalimumab achieved secondary endpoints other than for the health assessment questionnaire modified for spondyloarthritis. (medscape.com)
  • Too many of us are not as aggressive as we should be with using methotrexate initially," he said. (medscape.com)
  • Methotrexate was first made in 1947 and initially was used to treat cancer, as it was less toxic than the then-current treatments. (wikipedia.org)
  • Findings: Between Dec 24, 2014, and May 13, 2016, 247 patients were randomly allocated to pembrolizumab and 248 were randomly allocated to standard of care. (unige.ch)
  • The study included immunocompetent, adult patients with newly diagnosed PCNSL at 22 centers in China from 2007 to 2016. (biomedcentral.com)
  • Of all of the csDMARDs (conventional synthetic disease-modifying anti-rheumatic drugs) prescribed in this study cohort, methotrexate was the most common (prescribed for 33% of patients), with 41% of prescriptions being for the oral formulation and 59% for the parenteral version, which ranged from 7.5 to 20 mg per week. (medpagetoday.com)
  • Non-adherence was seen with both the oral and parenteral formulations of methotrexate, totaling 38% of patients. (medpagetoday.com)
  • Calcium folinate rescue has to be performed by parenteral administration in patients with malabsorption syndromes or other gastrointestinal disorders where enteral absorption is not assured. (janusinfo.se)
  • Twenty-two percent of cyclosporine-treated patients and 30% of methotrexate-treated patients developed interstitial pneumonia of any etiology (P = .25), and the figures for cytomegalovirus pneumonia were 18% and 20%, respectively (P = .41). (duke.edu)
  • To distinguish the degree of risk associated with methotrexate in populations with inflammatory disease, large prospective studies with longer follow-up are required. (hcplive.com)
  • Most of my patients are not on steroids," he said, "which is a godsend because of the great therapies we have. (medscape.com)
  • What this means, explained Gabay, was that clinicians learned which biomarkers to follow concerning the response of patients to this drug. (ajmc.com)
  • The guidelines draft was developed collaboratively with clinicians, researchers, and patients. (medscape.com)
  • Many clinicians recommend that the drug be used in patients with left-sided disease, restricted to the colon. (drugs.com)
  • Although methotrexate is often the first DMARD (disease modifying anti-rheumatic drug) which is prescribed to treat Rheumatoid Arthritis, it is still considered a dangerous drug. (rawarrior.com)
  • Methotrexate with dilation and curettage is used to treat molar pregnancy. (wikipedia.org)
  • Approximately one third of patients treated with methotrexate for gestational trophoblastic neoplasia (GTN) following a molar pregnancy are reported to develop resistance to methotrexate and need to change to different chemotherapeutic agents. (bvsalud.org)
  • Scholars@Duke publication: Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. (duke.edu)
  • The overall incidence of leukemic relapse was 31% in cyclosporine-treated patients and 36% in methotrexate-treated patients (P = .75). (duke.edu)